logo

Exclusive Market Insight

& Scientific analysis

subscribe today
  • Exclusive Posts
  • Industry Newsletters
  • Clinical Trials
  • Possible Takeovers
  • Technology of the Week
  • Stock Table
  • Therapeutic Vaccines
  • Development-Stage Firms
  • Genomics
  • Prohost Picks
  • And much more...
Trick or TradeToday’s HighlightsProhost LettersNews & CommentsImpacting NewsContact
Login

Category: Today’s Highlights

The Market Rebounding That Left Important Biotechnology Firms Behind

COVID-19, The Market Rebounding and the Biotech Firms That Did and Didn't Rally The Market Rebounding included: Amgen ( AMGN ) , Biogen ( BIIB ) and Incyte ( INCY ); t he only biotechnology firms to rebound in early...

Read More

March 13, 2020

0

Biogen discontinued its Alzheimer's disease drug Aducanumab. The usual selloff followed

Biogen’s (BIIB) decision to discontinue the global Phase 3 trials, ENGAGE and EMERGE which is designed to evaluate the efficacy and safety of its product aducanumab in patients with Alzheimer’s disease, has caused an exaggerated selloff of the stock. The...

Read More

March 21, 2019

0

Bluebird bio opens a state-of-the art gene and cell therapy manufacturing facility in Durham, NC

Governor Cooper to cut ribbon on bluebird bio facility Bluebird bio (BLUE) announced today, in its press release, the official opening of its first wholly owned manufacturing facility in Durham, N.C. The new facility will produce the lentiviral vector for...

Read More

March 22, 2019

0

Good News for Exelixis and for Japanese Renal Cell Carcinoma Patients

Exelixis, Takeda and Japanese RCC Patients Today we learned from Exelixis ( EXEL ) that Takeda Pharmaceutical Company Limited , which is responsible for the clinical development and commercialization of Exelixis' oncology drug   CABOMETYX® (cabozantinib) in Japan, informed that...

Read More

March 25, 2020

0

Regenxbio: Positive One-Year Data from the Firm's Gene Therapy RGX-314 for Wet AMD

Regenxbio Positive Data for RGX-314 Regenxbio ( RGNX ) reported positive one-year data from patients in Cohorts 4 and 5 from Phase I/IIa trial of RGX-314 for wet age-related macular degeneration ( wet AMD ). Regenxbio plans to initiate a...

Read More

August 4, 2020

0

Why Agios Pharmaceuticals’ product TIBSOVO® was granted FDA Breakthrough Therapy designation. The FDA approves Jazz Pharmaceuticals' product Sunosi

The uncontrolled blowing toxic wind contaminates this country’s environment, it brings down the oversold scientifically solid and promising biotech stocks together with the undersold disappointing firms’ stocks. All we want is peace of mind, fairness and well being for America...

Read More

March 27, 2019

0

Seattle Genetics: Why a selloff following good news

Following  Seattle Genetics' (SGEN)   and Astellas Pharma's   announcement of positive results, from pivotal trial of the conjugated monoclonal antibody drug Enfortumab Vedotin in locally advanced or metastatic urothelial cancer, the stock experienced a selloff . Prohost Observations  ...

Read More

March 29, 2019

0

Why We Are Still Optimistic. See Also: Inovio's Good News

COVID-19 and the Nation's Hospitals Disagreeable news with regard to the nation's hospitals is their unpreparedness to face a sudden crisis, let alone an unexpected and unprecedented pandemic. The system the hospitals are running on has been causing problems for...

Read More

March 27, 2020

0

Novartis' Revolution: A new dimension and Prohost expectations

The Market is Outperforming Today. There is important news today about Novartis; part of which we are posting now. There is still more news related to Novartis as well as other biotech and biopharmaceutical companies. All will be in the...

Read More

April 1, 2019

0

Two Companies Coronavirus Will Fail To Disrupt

Vertex and Regeneron Will Survive the Coronavirus Market Vertex We picked Vertex ( VRTX ) on March 18, 2011 at $44.39. The stock closed at $218 at the end of 2019. It rallied in mid-February reaching $247.78 then the unexpected...

Read More

March 31, 2020

0

  • Previous
  • 1
  • 2
  • ...
  • 93
  • 94
  • 95
  • ...
  • 172
  • 173
  • Next

Search ProhostBiotech

Popular Links

23andMe Holding Co (ME)Abbott Laboratories (ABT)AbbVie Inc (ABBV)AbCelleraAbeona Therapeutics (ABEO)Ablynx (ABLX)AbVitro IncAcadia (ACAD)Acceleron Pharma (XLRN)AcelRx Pharmaceuticals (ACRX).Acorda Therapeutics Inc (ACOR)Acumen Pharmaceuticals (ABOS)AdaptImmune Therapeutics (ADAP)Adaptive BiotechnologiesADC Therapeutics (ADCT)Adimab LLCAdvanced Micro Devices (AMD)Advaxis (ADXS)Adverum Biotechnologies (ADVM)Aerie Pharmaceuticals (AERI)AgenTus TherapeuticsAgenus (AGEN)AgeX Therapeutics (AGE)Agilent Technologies (A)Agilis Biotherapeutics IncAgios Pharmaceuticals (AGIO)AIM ImmunoTech (AIM)Aimmune Therapeutics (AIMT)Akari Therapeutics (AKTX)Akashi TherapeuticsAkcea Therapeutics (AKCA)Akebia Therapeutics Inc (AKBA)Akero Therapeutics (AKRO)Akous Inc (a wholly owned subsidiary of Eli Lilly Company)Alder BioPharmaceuticals (ALDR)Alexion Pharmaceuticals (ALXN)Alkermes (ALKS)Allergan Plc (AGN)Allogene TherapeuticsAllogene Therapeutics (ALLO)

Recent

AstraZeneca Product Fasenra Approved in the US for Eosinophilic Granulomatosis with Polyangiitis 

September 19, 2024

0

The U.S. FDA Approves Novartis' Kisqali® to Reduce the Risk of Recurrence in People with HR+/HER2- Early Breast Cancer

September 18, 2024

0

AstraZeneca’s Imfinzi + Imjudo Demonstrated Unprecedented Overall Survival in Advanced Liver Cancer

September 17, 2024

0

Halozyme Therapeutics Announced FDA Approval of Roche’s Tecentriq Hybreza with ENHANZE

September 13, 2024

0

Johnson & Johnson Product TREMFYA® Receives U.S. FDA Approval

September 12, 2024

0

Prohost Biotech – Exclusive Biotech Research Copyright © 2026.
Privacy Policy